What is the current Catheter-Related Bloodstream Infections market size?

The Catheter-Related Bloodstream Infections market size is approximately USD 1.2 billion as of 2023.

What is the growth forecast for the CRBSIs market?

The CRBSIs market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driving future outlook.

What are the key drivers of the CRBSIs market?

Increasing healthcare costs and rising demand for infection control measures drive the CRBSIs market growth.

What are the major challenges facing the CRBSIs market?

Stringent regulatory requirements and high treatment costs are significant challenges in the CRBSIs market.

Which regions are the leaders in the CRBSIs market?

North America and Europe are the leading regions in the CRBSIs market due to advanced healthcare infrastructure.

Who are the top companies in the CRBSIs market?

Top companies include Becton Dickinson, Baxter International, and 3M, offering innovative infection control solutions.

What are the future opportunities in the CRBSIs market?

Emerging economies and technological advancements in infection control devices present future opportunities in the CRBSIs market.

How does technology impact the CRBSIs market?

Advances in antimicrobial coatings and device design significantly impact the CRBSIs market, reducing infection rates.

What is the current regulatory landscape for the CRBSIs market?

The CRBSIs market is regulated by FDA and EU guidelines, ensuring strict standards for infection control devices.

How will the CRBSIs market evolve in the next 5 years?

The CRBSIs market will evolve through increased adoption of antimicrobial technologies and growing demand for sterile devices.

Catheter-Related Bloodstream Infections (CRBSIs) Growth, Trends & Forecast Outlook 2033

Catheter-Related Bloodstream Infections (CRBSIs) by Type (/> Anti-microbial Agents, Antibiotic Lock Therapy), by Application (/> Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 104

Forecast Period: 2026 - 2033

Market Size: $8.9 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 104

Forecast Period: 2026 - 2033

Market Size: $8.9 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Catheter-Related Bloodstream Infections (CRBSIs) Market Overview

The Catheter-Related Bloodstream Infections (CRBSIs) market refers to the industry focused on preventing and treating infections related to catheters. As a critical aspect of healthcare, the CRBSIs market size is estimated to be around $4.6 billion. The growth outlook for this market is positive, with a market forecast indicating a compound annual growth rate (CAGR) of 6.5% during the forecast period from 2026 to 2033, driven by increasing awareness of hospital-acquired infections and the need for improved patient safety. The scope of this market encompasses various types of catheters, including central venous catheters, peripheral intravenous catheters, and urinary catheters, as well as related technologies and services.

Loading chart…

Key forces shaping the CRBSIs industry include technological advancements in catheter materials and design, regulatory requirements for infection control and patient safety, and changing consumer behavior towards healthcare services. The largest region for the CRBSIs market is North America, while the fastest-growing region is expected to be Asia-Pacific, driven by increasing healthcare expenditure and a growing demand for quality medical services. With its positive growth outlook and significant market size, the CRBSIs market presents opportunities for industry players to develop innovative solutions and expand their presence in this critical healthcare segment.

Report Overview

Report Attribute	Details
Market size value in 2025	8.90 million
Revenue forecast in 2033	15.52 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Glenmark Pharmaceuticals Ltd; Xellia Pharmaceuticals Ltd; Fresenius Medical Care; Merck & Co., Inc.; Geistlich Pharma AG; TauroPhar GmbH
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Catheter-Related Bloodstream Infections (CRBSIs) market is poised for significant growth, driven by increasing awareness and adoption of preventative measures. The Catheter-Related Bloodstream Infections (CRBSIs) market size is expected to expand substantially, with a favorable growth forecast.

Growth Drivers2 items

Advances in medical technology, such as antimicrobial-coated catheters and improved insertion techniques, are reducing the incidence of CRBSIs, thereby driving demand for effective prevention and treatment solutions.

The implementation of regulatory guidelines and industry standards for catheter use and maintenance is also fueling growth in the CRBSIs market, as healthcare providers seek to minimize the risk of infection and ensure compliance.

Restraints2 items

The high cost of implementation and maintenance of CRBSI prevention protocols, including staff training and equipment upgrades, may hinder adoption in resource-constrained healthcare settings.

Variations in clinical practices and guideline adherence across different regions and healthcare facilities can also impede the growth of the CRBSIs market, as inconsistent standards may lead to uneven demand for prevention and treatment solutions.

Opportunities2 items

The increasing prevalence of chronic diseases, such as diabetes and cancer, which often require prolonged catheter use, presents a significant opportunity for growth in the CRBSIs market, as the demand for effective prevention and treatment solutions rises.

The development of innovative products and technologies, such as antimicrobial-coated catheters and point-of-care diagnostic tests, can help address the growing need for CRBSI prevention and treatment, driving expansion in the CRBSIs market.

Challenges2 items

The complexity of CRBSI diagnosis and treatment poses a significant challenge, as it requires careful consideration of various factors, including patient condition, catheter type, and antimicrobial resistance patterns.

The need for ongoing education and training of healthcare professionals on CRBSI prevention and management best practices also presents a challenge, as it demands significant investment of time and resources.

Market Segmentation

Loading chart…

The Type segment in the Catheter-Related Bloodstream Infections (CRBSIs) market refers to the different types of catheters that can cause bloodstream infections. This segment is crucial in understanding the Catheter-Related Bloodstream Infections (CRBSIs) segmentation as it helps identify the specific catheter types that are more prone to causing infections. By analyzing this segment, stakeholders can develop targeted strategies to reduce the risk of CRBSIs associated with specific catheter types.

The Application segment in the Catheter-Related Bloodstream Infections (CRBSIs) market involves the various applications of catheters that can lead to bloodstream infections. This segment is vital in understanding the market taxonomy of CRBSIs as it highlights the different areas where catheters are used and the corresponding risk of infection. By examining this segment, stakeholders can identify opportunities to implement infection control measures and reduce the incidence of CRBSIs in specific applications.

Catheter-Related Bloodstream Infections (CRBSIs) Segmentation Breakdown7 items

Type

/> Anti-microbial Agents

Antibiotic Lock Therapy

Application

/> Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Regional Insights

Loading chart…

The Catheter-Related Bloodstream Infections (CRBSIs) market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market. The fastest-growing region is anticipated to be the Asia Pacific, driven by increasing adoption of advanced medical devices and growing infrastructure in the healthcare sector.

Key drivers for the North America region include policies supporting the use of antimicrobial/antiseptic impregnated catheters, investments in research and development, and a mature ecosystem. In Europe, drivers include demographics with an aging population, adoption of bundles and checklists to prevent CRBSIs, and infrastructure development in healthcare facilities. The Asia Pacific region is driven by investments in healthcare infrastructure, policies promoting the use of sterile catheters, and growing awareness about CRBSIs.

In Latin America, key drivers include demographics with a growing population, adoption of protocols for catheter insertion and maintenance, and investments in healthcare facilities. The Middle East & Africa region is driven by policies supporting the prevention of hospital-acquired infections, infrastructure development in the healthcare sector, and growing awareness about CRBSIs. The regional forecast indicates a significant growth potential in the CRBSIs market, driven by increasing adoption of preventive measures and growing awareness about the risks associated with catheter-related infections.

Competitive Landscape

The Catheter-Related Bloodstream Infections (CRBSIs) competitive landscape is moderately consolidated, with a mix of global players and local/regional companies. The market is driven by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players are focusing on product innovation and certifications to gain a competitive edge, while local/regional companies are concentrating on pricing and distribution to maintain their market share. The CRBSIs competitive landscape is characterized by high competition, with companies striving to differentiate themselves through various strategies.

Companies in the CRBSIs market are adopting various strategies to stay competitive, including M&A, partnerships, product launches, expansion, R&D, and localization. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. To overcome these challenges, companies are focusing on strategic initiatives such as regional expansion, innovation pipeline, and local manufacturing.

Glenmark Pharmaceuticals Ltd: regional expansion

Xellia Pharmaceuticals Ltd: vertical integration

Fresenius Medical Care: premium pricing

Merck & Co., Inc.: OEM tie-ups

Geistlich Pharma AG: innovation pipeline

TauroPhar GmbH: local manufacturing

Key Catheter-Related Bloodstream Infections (CRBSIs) Companies6 items

Glenmark Pharmaceuticals Ltd

Xellia Pharmaceuticals Ltd

Fresenius Medical Care

Merck & Co., Inc.

Geistlich Pharma AG

TauroPhar GmbH

Market Ecosystem

The Catheter-Related Bloodstream Infections (CRBSIs) ecosystem spans across upstream, midstream, and downstream segments, encompassing technology providers, integrators, channels, and end users. Value is created and captured through the development, manufacturing, and distribution of products and services aimed at preventing and treating CRBSIs. The ecosystem involves a complex interplay of various participants, each contributing to the overall goal of reducing the incidence of CRBSIs.

Raw material/component suppliers — providing materials for device manufacturing

OEMs / manufacturers — designing and producing CRBSI prevention devices

Technology providers — developing innovative solutions for CRBSI prevention

System integrators / EPCs — integrating CRBSI prevention solutions into healthcare systems

Distributors / channel partners — delivering CRBSI prevention products to healthcare facilities

Service providers / after-sales — offering maintenance and support for CRBSI prevention devices

Regulators/standards bodies — establishing guidelines and standards for CRBSI prevention devices

In the CRBSIs ecosystem, control points are influenced by regulators, standards bodies, and healthcare organizations, which dictate the adoption of CRBSI prevention devices and solutions. Dependency risks arise from input constraints, such as the availability of raw materials, and standards approvals, which can impact the development and distribution of products. Additionally, switching costs, partnerships, and interoperability requirements can affect the ecosystem's dynamics. As the ecosystem differs by region, with varying standards and regulations, understanding these nuances is crucial for navigating the complex CRBSIs ecosystem, which is essential for conducting a thorough value chain analysis.

Recent Industry Insights

The Catheter-Related Bloodstream Infections (CRBSIs) industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as the collaboration between medical device companies and healthcare providers, have focused on improving patient outcomes and reducing the incidence of CRBSIs. Mergers and acquisitions have also been prominent, with companies aiming to expand their product portfolios and strengthen their market presence.

Additionally, there have been notable product and technology launches, including antimicrobial catheters and advanced dressing materials. Regulatory changes, such as updated guidelines for catheter insertion and maintenance, have also impacted the CRBSIs industry. Furthermore, a shift in consumer and enterprise trends towards value-based care and patient-centered approaches has driven the demand for effective CRBSI prevention solutions, making the CRBSIs industry trends a critical area of focus for market players.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Catheter-Related Bloodstream Infections (CRBSIs) market outlook. The market attractiveness is moderate, driven by the need for effective prevention and treatment solutions. Competitive intensity is high, with key players investing in research and development to improve existing products and technologies.

The long-term outlook for the CRBSIs market is promising, with growth opportunities in emerging economies and increasing awareness about the importance of infection control. The innovation landscape is evolving, with a focus on developing antimicrobial and antimicrobial-coated catheters. However, the demand-supply balance is a concern, with key risk factors including regulatory challenges and reimbursement issues. Overall, the CRBSIs market outlook is positive, with opportunities for growth and innovation in the prevention and treatment of catheter-related infections.

11 items

1. Executive Summary

2. Catheter-Related Bloodstream Infections (CRBSIs) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Catheter-Related Bloodstream Infections (CRBSIs) Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Catheter-Related Bloodstream Infections (CRBSIs) Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Anti-microbial Agents

6.1.2. Antibiotic Lock Therapy

6.2. Global Catheter-Related Bloodstream Infections (CRBSIs) Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Hospital Pharmacies

6.2.2. Retail Pharmacies

6.2.3. Online Pharmacies

6.3. Global Catheter-Related Bloodstream Infections (CRBSIs) Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Catheter-Related Bloodstream Infections (CRBSIs) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Catheter-Related Bloodstream Infections (CRBSIs) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Catheter-Related Bloodstream Infections (CRBSIs) Market Competition by Key Manufacturers

8.1. Global Catheter-Related Bloodstream Infections (CRBSIs) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Catheter-Related Bloodstream Infections (CRBSIs): Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Glenmark Pharmaceuticals Ltd

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Xellia Pharmaceuticals Ltd

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Fresenius Medical Care

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Merck & Co., Inc.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Geistlich Pharma AG

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. TauroPhar GmbH

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Catheter-Related Bloodstream Infections (CRBSIs) Market

Figure 4: Global Catheter-Related Bloodstream Infections (CRBSIs) Market: Drivers

Figure 5: Global Catheter-Related Bloodstream Infections (CRBSIs) Market: Challenges

Figure 6: Global Catheter-Related Bloodstream Infections (CRBSIs) Market: Trends

Figure 7: Global Catheter-Related Bloodstream Infections (CRBSIs) Market: Opportunity

Figure 8: Global Catheter-Related Bloodstream Infections (CRBSIs) Market: Restraint

Figure 9: Global Catheter-Related Bloodstream Infections (CRBSIs) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Catheter-Related Bloodstream Infections (CRBSIs) Market Value (USD Million) By Region

Figure 15: Global Catheter-Related Bloodstream Infections (CRBSIs) Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Catheter-Related Bloodstream Infections (CRBSIs) Market Value (USD Million) By Region

Figure 23: Global Catheter-Related Bloodstream Infections (CRBSIs) Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

65 items

Table 1: Market Segmentation Analysis

Table 2: Global Catheter-Related Bloodstream Infections (CRBSIs) Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Catheter-Related Bloodstream Infections (CRBSIs) Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Catheter-Related Bloodstream Infections (CRBSIs) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Catheter-Related Bloodstream Infections (CRBSIs) Market Value (USD Million) By Region

Table 10: Global Catheter-Related Bloodstream Infections (CRBSIs) Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Catheter-Related Bloodstream Infections (CRBSIs) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Catheter-Related Bloodstream Infections (CRBSIs) Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Catheter-Related Bloodstream Infections (CRBSIs) Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Glenmark Pharmaceuticals Ltd Basic Information And Sales Area

Table 31: Glenmark Pharmaceuticals Ltd. Products Portfolio

Table 32: Xellia Pharmaceuticals Ltd Basic Information And Sales Area

Table 33: Xellia Pharmaceuticals Ltd. Products Portfolio

Table 34: Fresenius Medical Care Basic Information And Sales Area

Table 35: Fresenius Medical Care. Products Portfolio

Table 36: Merck & Co., Inc. Basic Information And Sales Area

Table 37: Merck & Co., Inc.. Products Portfolio

Table 38: Geistlich Pharma AG Basic Information And Sales Area

Table 39: Geistlich Pharma AG. Products Portfolio

Table 40: TauroPhar GmbH Basic Information And Sales Area

Table 41: TauroPhar GmbH. Products Portfolio

Table 42: Global Market Value (USD Million) (2025-2032) By Type

Table 43: Global Market Share (%) By Type (2032)

Table 44: Global Market Value (USD Million) (2025-2032) By Application

Table 45: Global Market Share (%) By Application (2032)

Table 46: Global Catheter-Related Bloodstream Infections (CRBSIs) Market Value (USD Million) By Region

Table 47: Global Catheter-Related Bloodstream Infections (CRBSIs) Market Share (%) By Region (2025-2032)

Table 48: North America Market Value (USD Million) (2025-2032) By Country

Table 49: North America Market Value (USD Million) (2025-2032) By Type

Table 50: North America Market Value (USD Million) (2025-2032) By Application

Table 51: Europe Market Value (USD Million) (2025-2032) By Country

Table 52: Europe Market Value (USD Million) (2025-2032) By Type

Table 53: Europe Market Value (USD Million) (2025-2032) By Application

Table 54: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 55: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 56: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 57: South America Market Value (USD Million) (2025-2032) By Country

Table 58: South America Market Value (USD Million) (2025-2032) By Type

Table 59: South America Market Value (USD Million) (2025-2032) By Application

Table 60: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 61: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 62: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 63: Research Programs/Design For This Report

Table 64: Key Data Information From Secondary Sources

Table 65: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Catheter-Related Bloodstream Infections (CRBSIs) Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	8.90 million
Revenue forecast in 2033	15.52 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Glenmark Pharmaceuticals Ltd; Xellia Pharmaceuticals Ltd; Fresenius Medical Care; Merck & Co., Inc.; Geistlich Pharma AG; TauroPhar GmbH
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

The high cost of implementation and maintenance of CRBSI prevention protocols, including staff training and equipment upgrades, may hinder adoption in resource-constrained healthcare settings.

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Catheter-Related Bloodstream Infections (CRBSIs) Segmentation Breakdown7 items

Type

/> Anti-microbial Agents

Antibiotic Lock Therapy

Application

/> Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Regional Insights

Loading chart…

Competitive Landscape

Glenmark Pharmaceuticals Ltd: regional expansion

Xellia Pharmaceuticals Ltd: vertical integration

Fresenius Medical Care: premium pricing

Merck & Co., Inc.: OEM tie-ups

Geistlich Pharma AG: innovation pipeline

TauroPhar GmbH: local manufacturing

Key Catheter-Related Bloodstream Infections (CRBSIs) Companies6 items

Glenmark Pharmaceuticals Ltd

Xellia Pharmaceuticals Ltd

Fresenius Medical Care

Merck & Co., Inc.

Geistlich Pharma AG

TauroPhar GmbH

Market Ecosystem

Raw material/component suppliers — providing materials for device manufacturing

OEMs / manufacturers — designing and producing CRBSI prevention devices

Technology providers — developing innovative solutions for CRBSI prevention

System integrators / EPCs — integrating CRBSI prevention solutions into healthcare systems

Distributors / channel partners — delivering CRBSI prevention products to healthcare facilities

Service providers / after-sales — offering maintenance and support for CRBSI prevention devices

Regulators/standards bodies — establishing guidelines and standards for CRBSI prevention devices

Recent Industry Insights

Analyst Overview

Table of Contents